InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.032 -0.006 (-15.79%)+
Announcement
Release
29 Apr 2026 9:04AM
Price at Release
$0.038
Full Release
download
Summary
Argent BioPharma Limited, listed on the ASX as RGT, has released its Quarterly Activities Report and Appendix 4C Cash Flow Statement for the quarter ending March 2026. Key updates include the completion of the acquisition of a 48% interest in CannPal Animal Therapeutics Pty Ltd, enhancing its veterinary programme targeting seizure management in dogs. This acquisition aligns with Argent's broader neuro-immune strategy and supports its CannEpil® programme. The company has also dispatched its largest shipment of CannEpil® to Ireland, valued at approximately A$783,000, strengthening its European distribution. Financially, the company reported operating outflows of A$788k, with a closing cash balance of A$736k. Additionally, Argent filed a U.S. provisional patent for its NanoBodies platform, targeting septic shock and systemic inflammation, expanding its portfolio and reinforcing its intellectual property position.
Key Points
  • Completed acquisition of 48% interest in CannPal Animal Therapeutics Pty Ltd.
  • Largest commercial shipment of CannEpil® delivered to Ireland.
  • Filed U.S. provisional patent for NanoBodies platform targeting septic shock.
  • Operating outflows of A$788k; closing cash balance A$736k.
  • Strategic expansion of neuro-immune strategy with CannEpil® and NanoBodies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.